Alignment Healthcare’s CFO sells $1.5 million in stock

Robert L. Scavo, Chief Information Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), recently sold a significant portion of his common stock holdings in the company. According to a filing with the Securities and Exchange Commission, Scavo sold a total of 100,863 shares over two days, resulting in proceeds of approximately $1.5 million. The sale comes as the healthcare company, currently valued at $2.99 billion, has seen its stock surge 86% over the past year.

The transactions occurred on June 10 and June 11, 2025. On June 10, Scavo sold 60,000 shares at a price of $14.6008 per share. The following day, he sold an additional 40,863 shares at a weighted-average price of $15.2022 per share, with shares trading within a range of $15.10 to $15.51. According to InvestingPro analysis, ALHC is currently trading near its Fair Value, following a strong 35% price increase over the past six months.

These sales were conducted under a pre-established Rule 10b5-1 trading plan, which Scavo adopted on March 11, 2025. Following these transactions, Scavo retains ownership of 602,090 shares of Alignment Healthcare. For deeper insights into ALHC’s valuation and more exclusive analysis, check out the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Alignment Healthcare reported its first-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of -0.05 compared to the forecasted -0.13. The company’s revenue also exceeded projections, reaching $926.9 million against the anticipated $887.04 million. This marks a 47% year-over-year increase in revenue, with significant improvements in profitability metrics. The company is preparing for market expansion in 2026 and announced the appointment of a new CFO, Jim Head, succeeding Thomas Freeman. In addition to these developments, Alignment Healthcare’s membership grew by 32% year-over-year, totaling 217,500 members. The company also reported an adjusted gross profit of $107 million, an 87% increase from the previous year. Analysts from firms like William Blair and Baird noted the company’s strong performance and discussed potential future growth and strategic initiatives. The company’s strategic focus remains on enhancing patient engagement and care delivery, as emphasized by CEO John Kayo and outgoing CFO Thomas Freeman.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.